摘要
目的探究急性加重期慢性阻塞性肺病应用阿奇霉素治疗的临床效果及对血清炎性水平的影响。方法选择本院2020年1月-2021年1月收治的96例急性加重期慢性阻塞性肺病患者为研究对象,按照治疗药物不同均分为参照组和观察组,每组各48例。其中,参照组给予布地奈德福莫特罗粉吸入剂治疗,观察组给予阿奇霉素治疗,评估分析两组临床治疗效果;对比分析两组治疗前后肺功能指标改善情况、血清炎性水平改善情况及临床并发症发生情况。结果观察组临床治疗有效率为97.92%(47例),明显高于参照组的85.42%(41例),组间对比差异具有统计学意义(P<0.05)。治疗前,两组肺功能指标情况对比无明显差异(P>0.05);治疗后,观察组肺功能指标改善情况明显优于参照组,组间对比差异具有统计学意义(P<0.05)。治疗前,两组炎性因子(TNF-α、IL-6、IL-8)指标情况对比无明显差异(P>0.05);治疗后,观察组炎性因子(TNF-α、IL-6、IL-8)指标改善情况明显优于参照组,组间对比差异具有统计学意义(P<0.05)。观察组临床并发症发生率为8.32%(4例),明显低于参照组的25.00%(12例),组间对比差异具有统计学意义(P<0.05)。结论阿奇霉素治疗急性加重期慢性阻塞性肺疾病临床效果显著,同时可以明显改善患者肺功能指标情况,有效降低患者炎性因子,降低并发症发生。
Objective To investigate clinical effect of azithromycin on acute exacerbation of chronic obstructive pulmonary disease and effect on serum inflammatory levels.Methods The paper chose 96 patients with acute exacerbation chronic obstructive pulmonary disease admitted to our hospital from January 2020 to January 2021 as research objects,and divided them into reference group and observation group according to different drug treatments,with 48 cases in each group,(P<0.05).Among them,reference group was treated with budesonide and formoterol powder inhalation,while observation group with azithromycin.Clinical treatment effect between two groups was evaluated and analyzed,improvement of lung function indicators,serum inflammatory levels and clinical complications between two groups before and after treatment were compared and analyzed.Results Clinical treatment effective rate of observation group was 47(97.92%),significantly higher than 41(85.42%)of reference group,difference between the groups was statistically significant(P<0.05).Before treatment,there was no significant difference in lung function indicators between two groups(P>0.05).After treatment,improvement of lung function indicators in observation group was significantly better than reference group,difference between the groups was statistically significant,(P<0.05).Before treatment,inflammatory factors comparison,including(TNF-α,IL-6 and IL-8 indicators)showed no significant difference in between two groups,(P>0.05).After treatment,inflammatory factors improvement of(TNF)-α,IL-6 and IL-8 in observation group were significantly better than reference group,difference between the groups was statistically significant(P<0.05).Incidence of clinical complications in observation group was 4 cases(8.32%),significantly lower than 12 cases(25.00%)of reference group,difference between the groups was statistically significant(P<0.05).Conclusion Azithromycin can achieve significant clinical effect in treatment of acute exacerbation of chronic obstructive pulmonary disease,improve lung function indicators of patients significantly,reduce inflammatory factors and incidence of complications effectively.
作者
姚正鸿
YAO Zhenghong(Lizhai Branch,Zhangye City Minle County Xintian Center Health Center,Zhangye,Gansu 734505)
出处
《智慧健康》
2023年第16期183-186,共4页
Smart Healthcare
关键词
阿奇霉素
布地奈德福莫特罗粉吸入剂
加重期
慢性阻塞性肺病
Azithromycin
Budesonide formoterol powder inhaler
Aggravation period
Chronic obstructive pulmonary disease
